Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center forInternational Blood and Marrow Transplant Research Study

Philippe Armand, Haesook T. Kim, Mei Jie Zhang, Waleska S. Perez, Paola S. Dal Cin, Thomas R. Klumpp, Edmund K. Waller, Mark R. Litzow, Jane L. Liesveld, Hillard M. Lazarus, Andrew S. Artz, Vikas Gupta, Bipin N. Savani, Philip L. McCarthy, Jean Yves Cahn, Harry C. Schouten, Jürgen Finke, Edward D. Ball, Mahmoud D. Aljurf, Corey S. CutlerJacob M. Rowe, Joseph H. Antin, Luis M. Isola, Paolo Di Bartolomeo, Bruce M. Camitta, Alan M. Miller, Mitchell S. Cairo, Keith Stockerl-Goldstein, Jorge Sierra, M. Lynn Savoie, Joerg Halter, Patrick J. Stiff, Chadi Nabhan, Ann A. Jakubowski, Donald W. Bunjes, Effie W. Petersdorf, Steven M. Devine, Richard Maziarz, Martin Bornhauser, Victor A. Lewis, David I. Marks, Christopher N. Bredeson, Robert J. Soiffer, Daniel J. Weisdorf

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Cytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia (AML). However, existing cytogenetics classifications were developed in chemotherapy-treated patients and might not be optimal for patients undergoing allogeneic hematopoietic cell transplantation (HCT). We studied 821 adult patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) who underwent HCT for AML in first or second complete remission between 1999 and 2004. We compared the ability of the 6 existing classifications to stratify patients by overall survival. We then defined a new scheme specifically applicable to patients undergoing HCT using this patient cohort. Under this scheme, inv(16) is favorable, a complex karyotype (4 or more abnormalities) is adverse, and all other classified abnormalities are intermediate in predicting survival after HCT (5-year overall survival, 64%, 18%, and 50%, respectively; P = .0001). This scheme stratifies patients into 3 groups with similar nonrelapse mortality, but significantly different incidences of relapse, overall and leukemia-free survival. It applies to patients regardless of disease status (first or second complete remission), donor type (matched related or unrelated), or conditioning intensity (myeloablative or reduced intensity). This transplantation-specific classification could be adopted for prognostication purposes and to stratify patients with AML and karyotypic abnormalities entering HCT clinical trials.

Original languageEnglish (US)
Pages (from-to)280-288
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Homologous Transplantation
Acute Myeloid Leukemia
Cytogenetics
Bone Marrow
Transplants
Cell Transplantation
Research
Survival
Karyotype
Leukemia
Transplantation
Tissue Donors
Clinical Trials
Recurrence
Drug Therapy
Mortality
Incidence

Keywords

  • AML
  • Karyotype
  • SCT

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation : A Center forInternational Blood and Marrow Transplant Research Study. / Armand, Philippe; Kim, Haesook T.; Zhang, Mei Jie; Perez, Waleska S.; Dal Cin, Paola S.; Klumpp, Thomas R.; Waller, Edmund K.; Litzow, Mark R.; Liesveld, Jane L.; Lazarus, Hillard M.; Artz, Andrew S.; Gupta, Vikas; Savani, Bipin N.; McCarthy, Philip L.; Cahn, Jean Yves; Schouten, Harry C.; Finke, Jürgen; Ball, Edward D.; Aljurf, Mahmoud D.; Cutler, Corey S.; Rowe, Jacob M.; Antin, Joseph H.; Isola, Luis M.; Di Bartolomeo, Paolo; Camitta, Bruce M.; Miller, Alan M.; Cairo, Mitchell S.; Stockerl-Goldstein, Keith; Sierra, Jorge; Savoie, M. Lynn; Halter, Joerg; Stiff, Patrick J.; Nabhan, Chadi; Jakubowski, Ann A.; Bunjes, Donald W.; Petersdorf, Effie W.; Devine, Steven M.; Maziarz, Richard; Bornhauser, Martin; Lewis, Victor A.; Marks, David I.; Bredeson, Christopher N.; Soiffer, Robert J.; Weisdorf, Daniel J.

In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 2, 02.2012, p. 280-288.

Research output: Contribution to journalArticle

Armand, P, Kim, HT, Zhang, MJ, Perez, WS, Dal Cin, PS, Klumpp, TR, Waller, EK, Litzow, MR, Liesveld, JL, Lazarus, HM, Artz, AS, Gupta, V, Savani, BN, McCarthy, PL, Cahn, JY, Schouten, HC, Finke, J, Ball, ED, Aljurf, MD, Cutler, CS, Rowe, JM, Antin, JH, Isola, LM, Di Bartolomeo, P, Camitta, BM, Miller, AM, Cairo, MS, Stockerl-Goldstein, K, Sierra, J, Savoie, ML, Halter, J, Stiff, PJ, Nabhan, C, Jakubowski, AA, Bunjes, DW, Petersdorf, EW, Devine, SM, Maziarz, R, Bornhauser, M, Lewis, VA, Marks, DI, Bredeson, CN, Soiffer, RJ & Weisdorf, DJ 2012, 'Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center forInternational Blood and Marrow Transplant Research Study', Biology of Blood and Marrow Transplantation, vol. 18, no. 2, pp. 280-288. https://doi.org/10.1016/j.bbmt.2011.07.024
Armand, Philippe ; Kim, Haesook T. ; Zhang, Mei Jie ; Perez, Waleska S. ; Dal Cin, Paola S. ; Klumpp, Thomas R. ; Waller, Edmund K. ; Litzow, Mark R. ; Liesveld, Jane L. ; Lazarus, Hillard M. ; Artz, Andrew S. ; Gupta, Vikas ; Savani, Bipin N. ; McCarthy, Philip L. ; Cahn, Jean Yves ; Schouten, Harry C. ; Finke, Jürgen ; Ball, Edward D. ; Aljurf, Mahmoud D. ; Cutler, Corey S. ; Rowe, Jacob M. ; Antin, Joseph H. ; Isola, Luis M. ; Di Bartolomeo, Paolo ; Camitta, Bruce M. ; Miller, Alan M. ; Cairo, Mitchell S. ; Stockerl-Goldstein, Keith ; Sierra, Jorge ; Savoie, M. Lynn ; Halter, Joerg ; Stiff, Patrick J. ; Nabhan, Chadi ; Jakubowski, Ann A. ; Bunjes, Donald W. ; Petersdorf, Effie W. ; Devine, Steven M. ; Maziarz, Richard ; Bornhauser, Martin ; Lewis, Victor A. ; Marks, David I. ; Bredeson, Christopher N. ; Soiffer, Robert J. ; Weisdorf, Daniel J. / Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation : A Center forInternational Blood and Marrow Transplant Research Study. In: Biology of Blood and Marrow Transplantation. 2012 ; Vol. 18, No. 2. pp. 280-288.
@article{3f7a892aa34845dea57acabbc74b9ed2,
title = "Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center forInternational Blood and Marrow Transplant Research Study",
abstract = "Cytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia (AML). However, existing cytogenetics classifications were developed in chemotherapy-treated patients and might not be optimal for patients undergoing allogeneic hematopoietic cell transplantation (HCT). We studied 821 adult patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) who underwent HCT for AML in first or second complete remission between 1999 and 2004. We compared the ability of the 6 existing classifications to stratify patients by overall survival. We then defined a new scheme specifically applicable to patients undergoing HCT using this patient cohort. Under this scheme, inv(16) is favorable, a complex karyotype (4 or more abnormalities) is adverse, and all other classified abnormalities are intermediate in predicting survival after HCT (5-year overall survival, 64{\%}, 18{\%}, and 50{\%}, respectively; P = .0001). This scheme stratifies patients into 3 groups with similar nonrelapse mortality, but significantly different incidences of relapse, overall and leukemia-free survival. It applies to patients regardless of disease status (first or second complete remission), donor type (matched related or unrelated), or conditioning intensity (myeloablative or reduced intensity). This transplantation-specific classification could be adopted for prognostication purposes and to stratify patients with AML and karyotypic abnormalities entering HCT clinical trials.",
keywords = "AML, Karyotype, SCT",
author = "Philippe Armand and Kim, {Haesook T.} and Zhang, {Mei Jie} and Perez, {Waleska S.} and {Dal Cin}, {Paola S.} and Klumpp, {Thomas R.} and Waller, {Edmund K.} and Litzow, {Mark R.} and Liesveld, {Jane L.} and Lazarus, {Hillard M.} and Artz, {Andrew S.} and Vikas Gupta and Savani, {Bipin N.} and McCarthy, {Philip L.} and Cahn, {Jean Yves} and Schouten, {Harry C.} and J{\"u}rgen Finke and Ball, {Edward D.} and Aljurf, {Mahmoud D.} and Cutler, {Corey S.} and Rowe, {Jacob M.} and Antin, {Joseph H.} and Isola, {Luis M.} and {Di Bartolomeo}, Paolo and Camitta, {Bruce M.} and Miller, {Alan M.} and Cairo, {Mitchell S.} and Keith Stockerl-Goldstein and Jorge Sierra and Savoie, {M. Lynn} and Joerg Halter and Stiff, {Patrick J.} and Chadi Nabhan and Jakubowski, {Ann A.} and Bunjes, {Donald W.} and Petersdorf, {Effie W.} and Devine, {Steven M.} and Richard Maziarz and Martin Bornhauser and Lewis, {Victor A.} and Marks, {David I.} and Bredeson, {Christopher N.} and Soiffer, {Robert J.} and Weisdorf, {Daniel J.}",
year = "2012",
month = "2",
doi = "10.1016/j.bbmt.2011.07.024",
language = "English (US)",
volume = "18",
pages = "280--288",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation

T2 - A Center forInternational Blood and Marrow Transplant Research Study

AU - Armand, Philippe

AU - Kim, Haesook T.

AU - Zhang, Mei Jie

AU - Perez, Waleska S.

AU - Dal Cin, Paola S.

AU - Klumpp, Thomas R.

AU - Waller, Edmund K.

AU - Litzow, Mark R.

AU - Liesveld, Jane L.

AU - Lazarus, Hillard M.

AU - Artz, Andrew S.

AU - Gupta, Vikas

AU - Savani, Bipin N.

AU - McCarthy, Philip L.

AU - Cahn, Jean Yves

AU - Schouten, Harry C.

AU - Finke, Jürgen

AU - Ball, Edward D.

AU - Aljurf, Mahmoud D.

AU - Cutler, Corey S.

AU - Rowe, Jacob M.

AU - Antin, Joseph H.

AU - Isola, Luis M.

AU - Di Bartolomeo, Paolo

AU - Camitta, Bruce M.

AU - Miller, Alan M.

AU - Cairo, Mitchell S.

AU - Stockerl-Goldstein, Keith

AU - Sierra, Jorge

AU - Savoie, M. Lynn

AU - Halter, Joerg

AU - Stiff, Patrick J.

AU - Nabhan, Chadi

AU - Jakubowski, Ann A.

AU - Bunjes, Donald W.

AU - Petersdorf, Effie W.

AU - Devine, Steven M.

AU - Maziarz, Richard

AU - Bornhauser, Martin

AU - Lewis, Victor A.

AU - Marks, David I.

AU - Bredeson, Christopher N.

AU - Soiffer, Robert J.

AU - Weisdorf, Daniel J.

PY - 2012/2

Y1 - 2012/2

N2 - Cytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia (AML). However, existing cytogenetics classifications were developed in chemotherapy-treated patients and might not be optimal for patients undergoing allogeneic hematopoietic cell transplantation (HCT). We studied 821 adult patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) who underwent HCT for AML in first or second complete remission between 1999 and 2004. We compared the ability of the 6 existing classifications to stratify patients by overall survival. We then defined a new scheme specifically applicable to patients undergoing HCT using this patient cohort. Under this scheme, inv(16) is favorable, a complex karyotype (4 or more abnormalities) is adverse, and all other classified abnormalities are intermediate in predicting survival after HCT (5-year overall survival, 64%, 18%, and 50%, respectively; P = .0001). This scheme stratifies patients into 3 groups with similar nonrelapse mortality, but significantly different incidences of relapse, overall and leukemia-free survival. It applies to patients regardless of disease status (first or second complete remission), donor type (matched related or unrelated), or conditioning intensity (myeloablative or reduced intensity). This transplantation-specific classification could be adopted for prognostication purposes and to stratify patients with AML and karyotypic abnormalities entering HCT clinical trials.

AB - Cytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia (AML). However, existing cytogenetics classifications were developed in chemotherapy-treated patients and might not be optimal for patients undergoing allogeneic hematopoietic cell transplantation (HCT). We studied 821 adult patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) who underwent HCT for AML in first or second complete remission between 1999 and 2004. We compared the ability of the 6 existing classifications to stratify patients by overall survival. We then defined a new scheme specifically applicable to patients undergoing HCT using this patient cohort. Under this scheme, inv(16) is favorable, a complex karyotype (4 or more abnormalities) is adverse, and all other classified abnormalities are intermediate in predicting survival after HCT (5-year overall survival, 64%, 18%, and 50%, respectively; P = .0001). This scheme stratifies patients into 3 groups with similar nonrelapse mortality, but significantly different incidences of relapse, overall and leukemia-free survival. It applies to patients regardless of disease status (first or second complete remission), donor type (matched related or unrelated), or conditioning intensity (myeloablative or reduced intensity). This transplantation-specific classification could be adopted for prognostication purposes and to stratify patients with AML and karyotypic abnormalities entering HCT clinical trials.

KW - AML

KW - Karyotype

KW - SCT

UR - http://www.scopus.com/inward/record.url?scp=84855584157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855584157&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2011.07.024

DO - 10.1016/j.bbmt.2011.07.024

M3 - Article

C2 - 21810400

AN - SCOPUS:84855584157

VL - 18

SP - 280

EP - 288

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -